Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2020 | KEYNOTE-199: an update on pembrolizumab for mCRPC

Emmanuel Antonarakis, MBBCh, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, gives us an update on the KEYNOTE-199 trial (NCT02787005), using pembrolizumab as monotherapy in men with metastatic castration-resistant prostate cancer (mCRPC), and the potential of combining pembrolizumab with docetaxel, enzalutamide or olaparib. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.